Abstract 103P
Background
For patients (pts) with advanced BTC with progression on gemcitabine plus cisplatin (GemCis), fluoropyrimidine-based chemotherapy, including liposomal irinotecan (nal-IRI) plus fluorouracil and leucovorin (5-FU/LV) and 5-FU/LV plus oxaliplatin (FOLFOX) showed clinical benefit in prior randomized trials (NIFTY and ABC-06). However, there is no trial for head-to-head comparison among these agents.
Methods
We performed IPD meta-analysis of two multicenter, randomized trials performed in South Korea, which compared efficacy of second-line chemotherapy for advanced BTC after progression on GemCis, including the phase 2b NIFTY trial (nal-IRI plus 5-FU/LV vs. 5-FU/LV, NCT03524508) and the phase 2 FIReFOX trial (modified FOLFOX [mFOLFOX] vs. modified 5-FU/LV plus irinotecan [mFOLFIRI], NCT03464968). ITT population of the two trials were included and survival outcomes were compared between the 4 treatment groups by pairwise log-rank test. Hazards ratio (HR) adjusted by potential prognostic variables was estimated by Cox proportional hazards modeling with shared frailty to account for the trials effect.
Results
A total of 278 pts were included in this analysis (178 pts from the NIFTY trial and 99 pts from the FIReFOX trial). The nal-IRI plus 5-FU/LV group (n=88) showed significantly better overall survival compared to the mFOLFOX group (n=49, p = 0.02), mFOLFIRI group (n=50, p = 0.03), and 5-FU/LV group (n=90, p = 0.008). Multivariable analysis showed consistent trends with adjusted HR of 1.44 (95% CI 0.93-2.07, p = 0.11), 1.36 (95% CI 0.92-2.03, p = 0.13), and 1.52 (95% CI 1.37-1.09-2.10, p = 0.01), respectively. Also, nal-IRI plus 5-FU/LV group showed trends toward better progression-free survival compared to the other 3 groups with adjusted HR of 1.44 (95% CI 0.98-2.11, p = 0.06), 1.29 (95% CI 0.87-1.89, p = 0.20), and 1.88 (1.38-2.55, p < 0.001), respectively.
Conclusions
Nal-IRI plus 5-FU/LV showed better survival outcomes when compared to mFOLFOX, mFOLFIRI, or 5-FU/LV alone. Nal-IRI plus 5-FU/LV may be a preferable second-line regimen for advanced BTC pts without targetable genetic alterations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Servier.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
720TiP - Phase I, open-label, first-in-human (FIH) study of JZP815 in advanced or metastatic solid tumors harboring mitogen-activated protein kinase (MAPK) alterations
Presenter: Abdul-Rafeh Naqash
Session: Poster session 17
722TiP - CLAUDIO-01: A multicentric phase I/II trial to evaluate the safety and efficacy of SOT102 as monotherapy and in combination with standard of care (SoC) in patients with gastric, gastroesophageal junction(GEJ), and pancreatic adenocarcinoma
Presenter: Radka Obermannova
Session: Poster session 17
732P - Efficacy and safety of high-dose chemotherapy as second or subsequent salvage therapy in relapsed or refractory germ cell cancer patients: A multicentric analysis
Presenter: Christoph Seidel
Session: Poster session 17
733P - Testicular cancer: Trends in incidence and demographics from 23,214 cases in California from 2000-2020
Presenter: David Benjamin
Session: Poster session 17
734P - Primary retroperitoneal germ-cell tumours (pR-GCT): Evaluation of treatment outcomes of an international collaboration (PRIMERE study-IGG05)
Presenter: Patrizia Giannatempo
Session: Poster session 17